Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1 with favorable safety pro no observed liver safety concerns 2 With global CIndU prevalence of 29 million 3,4; greater than 50% of patients experience significant disease burden despite treatment with H1-antihistamines; no approved targeted therapies exist 5,6 Rhapsido is under FDA review for CIndU symptomatic dermographism subtype; additional submissions to health au

Financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors Proceeds will support clinical advancement of lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closin

June 9, 2026 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for the Phase I ATTRACT study of ATG-20

– ETHY-001 targets the causal pathogenic mechanism underlying both conditions – – Patient-friendly subcutaneous administration with half-life extension for infrequent dosing – – First-in-human clinical trial expected to initiate in the second half of 2026 – – Preclinical data to be presented in an oral presentation at ENDO on June 15, 2026 – – Backed by leading healthcare investors including Atlas Venture, Medicxi Ventures, Avoro Capital, Nandi Life Sciences, and Checkpoint Capital – June 10, 2

Galmed Pharmaceuticals acquired Colospan in a $4.5 million deal as the Israel-based biotech looks to create a gastrointestinal platform targeting a dx sector valued at $6 billion. The deal calls for Colospan shareholders and SAFE (Simple Agreement for Future Equity) holders to get $2.5 million in cash and $2 million in common ordinary shares at the close, which is expected to be completed by the end of the second quarter this year, the company said in a June 8 press release. The sale has been

June 10, 2026 -- XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, today announced a strategic partnership with a prominent international biopharmaceutical company. The collaboration focuses on developing a best-in-class small molecule against a G protein-coupled receptor (GPCR). This agreement builds upon a rigorous and successful pilot phase, where XtalPi's integrated quantum physics and AI algorithms delivered breakthrough hit rates, conf

June 10, 2026 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced that the National Medical Products Administration (NMPA) of China has accepted the Investigational New Drug (IND) application for HBM7004 for the treatment of advanced solid tumors. HBM7004 is a novel B7H4xCD3 bispecific antibody developed using the Company's HBI

June 9, 2026 -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, today announced a significant clinical milestone achieved by its global partner, Formation Bio. Formation Bio announced the dosing of the first participant in a Phase 1, first-in-human clinical trial (BLKR201-101-HV) evaluating BLKR201 (originally designated as LNK01006). The study is a single ascending dose (SAD) and mult

Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at PSNI collaborates with Seattle-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier, and deliver proprietary immunotherapeutic directly into patients' tumors, rather than intravenously June 9, 2026 -- A collaboration involving Providence Swedish Neuroscience Institute (PSNI) recently concluded initial testing of a novel immunotherapy research project for the treatment of glioblastoma (GBM). Th

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young children Rare pediatric disease designation provides for a Priority Review Voucher (PRV) subject to certain conditions This new designation is in addition to opaganib's current neuroblastoma orphan drug designation, providing for potential benefits such as accelerated development and review times, F